TX-H3-DYNAMICS
H3 Dynamics is announcing the global launch of H2FIELD-1, a new hydrogen station capable of producing hydrogen in the field for unmanned aerial vehicles of all shapes, sizes and configurations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005066/en/
H3 Dynamics announces H2FIELD mobile hydrogen station for hydrogen drones and UAVs of all shapes and sizes, from hydrogen production to automatic refilling in the field. (Photo: Business Wire)
Now hydrogen-powered airships, multi-rotors, vertical take-off and landing UAS and various fixed wing systems will be able to benefit from 24/7 hydrogen supply anywhere, anytime.
H2FIELD’s rugged IP-65 trailer-based solution brings hydrogen production to different drone operation locations. It can also be dismounted as a permanent installation and connect to solar panel arrays. H3 Dynamics can supply various configurations, with slow or fast charge options down to minutes per fill - depending on client requirements. H3 Dynamics’ system is extremely compact and can produce hydrogen on site - not just dispense it from other storage forms.
For hydrogen drone operators, H2FIELD-1 solves fundamental hydrogen accessibility in remote areas, unlocking a major logistical barrier for a growing base of hydrogen drone operators in industrial, defense, or even academic sectors. The only feedstock input is water.
H3 Dynamics has been working on a first transatlantic hydrogen-electric flight using liquid hydrogen storage systems currently being tested in France with ISAE-SUPAERO in Toulouse. Last week H3 Dynamics announced its hydrogen propulsion partnership with French airship maker HyLight, and the week prior with Australian VTOL UAV producer Carbonix whose airframes are made by Quickstep - Australia’s leading aerospace composites producer.
2023 will see more of these announcements as H3 Dynamics continues to transition battery-UAS manufacturers to hydrogen technologies. Compared to batteries, hydrogen electric systems increase battery-drone flight durations by several orders of magnitude, opening to many new possibilities in a market that is expected to grow five-fold to $100B by 2030.
H2FIELD-1 marks the start of H3 Dynamics’ foray into hydrogen infrastructure solutions for small, unmanned and increasingly large aircraft, from airfields to airports - with increasingly large output power and hydrogen storage capabilities.
“We are the evolutionary starting point to increasingly large hydrogen powered flight platforms, where testing, certification and regulatory approval challenges vary based on aircraft weight. We want to mature hydrogen technology in today’s existing uncrewed aviation market - and that includes working out hydrogen logistics and refueling systems,” says Taras Wankewycz, CEO and co-Founder at H3 Dynamics.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is on a mission to decarbonize aviation. While the commercial opportunities around passenger-scale hydrogen aviation propulsion will take many more years to mature, the company is following a “start small” product and services roadmap that solves safety, technical, regulatory challenges by adding scale, weight and complexity over time. The company employs 94 team members from its 3 regional headquarters in Toulouse, Austin and Singapore. H3 Dynamics is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005066/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom